Article Text
Abstract
Objective Gastric adenocarcinoma (gastric cancer, GC) is a major cause of global cancer mortality. Identifying molecular programmes contributing to GC patient survival may improve our understanding of GC pathogenesis, highlight new prognostic factors and reveal novel therapeutic targets. The authors aimed to produce a comprehensive inventory of gene expression programmes expressed in primary GCs, and to identify those expression programmes significantly associated with patient survival.
Design Using a network-modelling approach, the authors performed a large-scale meta-analysis of GC transcriptome data integrating 940 gastric transcriptomes from multiple independent patient cohorts. The authors analysed a training set of 428 GCs and 163 non-malignant gastric samples, and a validation set of 288 GCs and 61 non-malignant gastric samples.
Results The authors identified 178 gene expression programmes (‘modules’) expressed in primary GCs, which were associated with distinct biological processes, chromosomal location patterns, cis-regulatory motifs and clinicopathological parameters. Expression of a transforming growth factor β (TGF-β) signalling associated ‘super-module’ of stroma-related genes consistently predicted patient survival in multiple GC validation cohorts. The proportion of intra-tumoural stroma, quantified by morphometry in tissue sections from gastrectomy specimens, was also significantly associated with stromal super-module expression and GC patient survival.
Conclusion Stromal gene expression predicts GC patient survival in multiple independent cohorts, and may be closely related to the intra-tumoural stroma proportion, a specific morphological GC phenotype. These findings suggest that therapeutic approaches targeting the GC stroma may merit evaluation.
- Gastric cancer
- gene expression
- prognostic factors
- oesophageal cancer
- molecular pathology
- carcinogenesis
- gastric adenocarcinoma
- colorectal cancer
- image analysis
- Helicobacter pylori–gastritis
- Barrett's metaplasia
- Barrett's carcinoma
- colorectal cancer screening
- gastric pre-cancer
- liver
- hepatoma
Statistics from Altmetric.com
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data Supplement 1 - Online Supplements
Footnotes
-
Funding This work was supported by Grants to PT from the Biomedical Research Council of Singapore (Grant 05/1/31/19/423), the National Medical Research Council of Singapore (Grant TCR/001/2007), and internal grants from the Duke-National University of Singapore Graduate Medical School, and the Cancer Sciences Institute of Singapore. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
-
Competing interests None.
-
Patient consent Obtained.
-
Ethics approval Primary gastric cancer tissue samples were collected with patient consent from the participating centre's tissue repositories or pathology archives and approval by the respective institutional Research Ethics Review Committees in accordance with local regulations and legislations. Clinical information was collected with Institutional Review Board approval.
-
Provenance and peer review Not commissioned; externally peer reviewed.
-
Data sharing statement The microarray data in this study is available from GEO under accession numbers GSE2669, GSE2680, GSE2685, GSE2637, GSE3438, GSE15459, GSE13861, GSE37023, GSE35809 and http://smd.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=516.